1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zhu H, Li T, Du Y and Li M: Pancreatic
cancer: Challenges and opportunities. BMC Med. 16:2142018.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Goto T, Fujiya M, Konishi H, Sasajima J,
Fujibayashi S, Hayashi A, Utsumi T, Sato H, Iwama T, Ijiri M, et
al: An elevated expression of serum exosomal microRNA-191, - 21,
−451a of pancreatic1 neoplasm is considered to be efficient
diagnostic marker. BMC Cancer. 18:1162018. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lin Y, Lin Z, Fang Z, Li H, Zhi X and
Zhang Z: Plasma MicroRNA-34a as a potential biomarker for early
diagnosis of esophageal cancer. Clin Lab. 65:2019. View Article : Google Scholar
|
6
|
Fadaka AO, Pretorius A and Klein A:
Functional prediction of candidate MicroRNAs for CRC management
using in silico approach. Int J Mol Sci. 20:E51902019. View Article : Google Scholar : PubMed/NCBI
|
7
|
Matsuzaki J and Ochiya T: Circulating
microRNAs and extracellular vesicles as potential cancer
biomarkers: A systematic review. Int J Clin Oncol. 22:413–420.
2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kawaguchi T, Komatsu S, Ichikawa D,
Tsujiura M, Takeshita H, Hirajima S, Miyamae M, Okajima W, Ohashi
T, Imamura T, et al: circulating MicroRNAs: A next-generation
clinical biomarker for digestive system cancers. Int J Mol Sci.
17:E14592016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Salehi M and Sharifi M: Exosomal miRNAs as
novel cancer biomarkers: Challenges and opportunities. J Cell
Physiol. 233:6370–6380. 2018. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wang L, Zhao F, Xiao Z and Yao L: Exosomal
microRNA-205 is involved in proliferation, migration, invasion, and
apoptosis of ovarian cancer cells via regulating VEGFA. Cancer Cell
Int. 19:2812019. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fang JH, Zhang ZJ, Shang LR, Luo YW, Lin
YF, Yuan Y and Zhuang SM: Hepatoma cell-secreted exosomal
microRNA-103 increases vascular permeability and promotes
metastasis by targeting junction proteins. Hepatology.
68:1459–1475. 2018. View Article : Google Scholar : PubMed/NCBI
|
12
|
Li XJ, Ren ZJ, Tang JH and Yu Q: Exosomal
MicroRNA MiR-1246 promotes cell proliferation, invasion and drug
resistance by targeting CCNG2 in breast cancer. Cell Physiol
Biochem. 44:1741–1748. 2017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wu Y, Kwak KJ, Agarwal K, Marras A, Wang
C, Mao Y, Huang X, Ma J, Yu B, Lee R, et al: Detection of
extracellular RNAs in cancer and viral infection via tethered
cationic lipoplex nanoparticles containing molecular beacons. Anal
Chem. 85:11265–11274. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lee LJ, Yang Z, Rahman M, Ma J, Kwak KJ,
McElroy J, Shilo K, Goparaju C, Yu L, Rom W, et al: Extracellular
mRNA detected by tethered lipoplex nanoparticle biochip for lung
adenocarcinoma detection. Am J Respir Crit Care Med. 193:1431–1433.
2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hu J, Kwak KJ, Shi J, Yu B, Sheng Y and
Lee LJ: Overhang molecular beacons encapsulated in tethered
cationic lipoplex nanoparticles for detection of single-point
mutation in extracellular vesicle-associated RNAs. Biomaterials.
183:20–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
16
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
17
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
MiR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Hong L, Han Y, Zhang Y, Zhang H, Zhao Q,
Wu K and Fan D: MicroRNA-21: A therapeutic target for reversing
drug resistance in cancer. Expert Opin Ther Targets. 17:1073–1080.
2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sheth S, Jajoo S, Kaur T, Mukherjea D,
Sheehan K, Rybak LP and Ramkumar V: Resveratrol reduces prostate
cancer growth and metastasis by inhibiting the
Akt/MicroRNA-21pathway. PLoS One. 7:e516552012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Xiong B, Cheng Y, Ma L and Zhang C: MiR-21
regulates biological behavior through the PTEN/PI-3 K/Akt signaling
pathway in human colorectal cancer cells. Int J Oncol. 42:219–228.
2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Qian X, Ren Y, Shi Z, Long L, Pu P, Sheng
J, Yuan X and Kang C: Sequence-dependent synergistic inhibition of
human glioma cell lines by combined temozolomide and miR-21
inhibitor gene therapy. Mol Pharm. 9:2636–2645. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lai X and Friedman A: Exosomal miRs in
lung cancer: A mathematical model. PLoS One. 11:e01677062016.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Bica-Pop C, Cojocneanu-Petric R, Magdo L,
Raduly L, Gulei D and Berindan-Neagoe I: Overview upon miR-21 in
lung cancer: Focus on NSCLC. Cell Mol Life Sci. 75:3539–3551. 2018.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Wang M, Ji S, Shao G, Zhang J, Zhao K,
Wang Z and Wu A: Effect of exosome biomarkers for diagnosis and
prognosis of breast cancer patients. Clin Transl Oncol. 20:906–911.
2018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Kim J, Siverly AN, Chen D, Wang M, Yuan Y,
Wang Y, Lee H, Zhang J, Muller WJ, Liang H, et al: Ablation of
miR-10b suppresses oncogene-induced mammary tumorigenesis and
metastasis and reactivates tumor-suppressive pathways. Cancer Res.
76:6424–6435. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai
X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived
exosomal miRNA as potential diagnostic biomarkers for early-stage
non-small cell lung cancer using next-generation sequencing. Clin
Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ayaz L, Görür A, Yaroğlu HY, Ozcan C and
Tamer L: Differential expression of microRNAs in plasma of patients
with laryngeal squamous cell carcinoma: Potential early-detection
markers for laryngeal squamous cell carcinoma. J Cancer Res Clin
Oncol. 139:1499–1506. 2013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Stetefeld J, McKenna SA and Patel TR:
Dynamic light scattering: A practical guide and applications in
biomedical sciences. Biophys Rev. 8:409–427. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Fischer K and Schmidt M: Pitfalls and
novel applications of particle sizing by dynamic light scattering.
Biomaterials. 98:79–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Parikh R, Mathai A, Parikh S, Chandra
Sekhar G and Thomas R: Understanding and using sensitivity,
specificity and predictive values. Indian J Ophthalmol. 56:45–50.
2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Simpson RJ, Lim JW, Moritz RL and
Mathivanan S: Exosomes: Proteomic insights and diagnostic
potential. Expert Rev Proteomics. 6:267–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
32
|
Root A, Allen P, Tempst P and Yu K:
Protein biomarkers for early detection of pancreatic ductal
adenocarcinoma: Progress and challenges. Cancers (Basel).
10:E672018. View Article : Google Scholar : PubMed/NCBI
|
33
|
Lennon AM, Wolfgang CL, Canto MI, Klein
AP, Herman JM, Goggins M, Fishman EK, Kamel I, Weiss MJ, Diaz LA,
et al: The early detection of pancreatic cancer: What will it take
to diagnose and treat curable pancreatic neoplasia? Cancer Res.
74:3381–3389. 2018. View Article : Google Scholar
|
34
|
Duell EJ, Lujan-Barroso L, Sala N, Deitz
McElyea S, Overvad K, Tjonneland A, Olsen A, Weiderpass E, Busund
LT, Moi L, et al: Plasma microRNAs as biomarkers of pancreatic
cancer risk in a prospective cohort study. Int J Cancer.
141:905–915. 2017. View Article : Google Scholar : PubMed/NCBI
|
35
|
Ouyang H, Gore J, Deitz S and Korc M:
MicroRNA-10b enhances pancreatic cancer cell invasion by
suppressing TIP30 expression and promoting EGF and TGF-β actions.
Oncogene. 36:49522017. View Article : Google Scholar : PubMed/NCBI
|
36
|
Jamali L, Tofigh R, Tutunchi S, Panahi G,
Borhani F, Akhavan S, Nourmohammadi P, Ghaderian SMH, Rasouli M and
Mirzaei H: Circulating microRNAs as diagnostic and therapeutic
biomarkers in gastric and esophageal cancers. J Cell Physiol.
233:8538–8550. 2018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Shan X, Zhang H, Zhang L, Zhou X, Wang T,
Zhang J, Shu Y, Zhu W, Wen W and Liu P: Identification of four
plasma microRNAs as potential biomarkers in the diagnosis of male
lung squamous cell carcinoma patients in China. Cancer Med.
7:2370–2381. 2018. View Article : Google Scholar : PubMed/NCBI
|
38
|
Matamala N, Vargas MT, González-Cámpora R,
Miñambres R, Arias JI, Menéndez P, Andrés-León E, Gómez-López G,
Yanowsky K, Calvete-Candenas J, et al: Tumor microRNA expression
profiling identifies circulating microRNAs for early breast cancer
detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
|
39
|
Lai X, Wang M, McElyea SD, Sherman S,
House M and Korc M: A microRNA signature in circulating exosomes is
superior to exosomal glypican-1 levels for diagnosing pancreatic
cancer. Cancer Lett. 393:86–93. 2017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Joshi GK, Deitz-McElyea S, Liyanage T,
Lawrence K, Mali S, Sardar R and Korc M: Label-free
nanoplasmonic-based short noncoding RNA sensing at attomolar
concentrations allows for quantitative and highly specific assay of
MicroRNA-10b in biological fluids and circulating exosomes. ACS
Nano. 9:11075–11089. 2015. View Article : Google Scholar : PubMed/NCBI
|
41
|
Wu R, Li F, Zhu J, Tang R, Qi Q, Zhou X,
Li R, Wang W, Hua D and Chen W: A functional variant at miR-132-3p,
miR-212-3p, and miR-361-5p binding site in CD80 gene alters
susceptibility to gastric cancer in a Chinese Han population. Med
Oncol. 31:602014. View Article : Google Scholar : PubMed/NCBI
|
42
|
Wu Z, Zhou L, Ding G and Cao L:
Overexpressions of miR-212 are associated with poor prognosis of
patients with pancreatic ductal adenocarcinoma. Cancer Biomark.
18:35–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
43
|
Maisonneuve P and Lowenfels AB: Risk
factors for pancreatic cancer: A summary review of meta-analytical
studies. Int J Epidemiol. 44:186–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
44
|
Li X, Xu H and Gao P: ABO blood group and
diabetes mellitus influence the risk for pancreatic cancer in a
population from China. Med Sci Monit. 24:9392–9398. 2018.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Bloomston M, Frankel WL, Petrocca F,
Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce
CM: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
46
|
Abue M, Yokoyama M, Shibuya R, Tamai K,
Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K
and Satoh K: Circulating miR-483-3p and miR-21 is highly expressed
in plasma of pancreatic cancer. Int J Oncol. 46:539–547. 2015.
View Article : Google Scholar : PubMed/NCBI
|